TPIDB > Principal Investigator
Principal Investigator
National Taiwan University Hospital
(在職)
Division of General Internal Medicine
Division of Hematology & Oncology
Division of General Surgery
National Taiwan University Hospital Hsin-Chu Branch
Division of General Internal Medicine
Division of Hematology & Oncology
National Taiwan University Cancer Center
Division of Hematology & Oncology
更新時間：2023-09-19
盧彥伸LU, YEN-SHEN
- Principal Investigator
- Clinical Trial Experience (year) 22 years 9 個月
Publication
26Publications
21
Kuo CT, Chen CL, Li CC, Huang GS, Ma WY, Hsu WF, Lin CH, Lu YS, Wo AM. Immunofluorescence can assess the efficacy of mTOR pathway therapeutic agent Everolimus in breast cancer models. Sci Rep. 2019 Jul 29;9(1):10898. doi: 10.1038/s41598-019-45319-4. Erratum in: Sci Rep. 2020 Aug 19;10(1):14139. PMID: 31358767; PMCID: PMC6662705.
22
Yang MH, Chen IC, Lu YS. PI3K inhibitor provides durable response in metastatic metaplastic carcinoma of the breast: A hidden gem in the BELLE-4 study. J Formos Med Assoc. 2019 Sep;118(9):1333-1338. doi: 10.1016/j.jfma.2018.12.004. Epub 2018 Dec 18. PMID: 30577988.
23
Yap YS, Lu YS, Tamura K, Lee JE, Ko EY, Park YH, Cao AY, Lin CH, Toi M, Wu J, Lee SC. Insights Into Breast Cancer in the East vs the West: A Review. JAMA Oncol. 2019 Oct 1;5(10):1489-1496. doi: 10.1001/jamaoncol.2019.0620. PMID: 31095268.
24
Iwata H, Masuda N, Kim SB, Inoue K, Rai Y, Fujita T, Chiu J, Ohtani S, Takahashi M, Miyaki T, Lu YS, Xu B, Yap YS, Bustam A, Yao B, Zhang B, Bryce R, Chan A. Neratinib after trastuzumab-based adjuvant therapy in patients from Asia with early stage HER2-positive breast cancer. Future Oncol. 2019 Jul;15(21):2489-2501.
25
Tripathy D, Im SA, Colleoni M, Franke F, Bardia A, Harbeck N, Hurvitz SA, Chow L, Sohn J, Lee KS, Campos-Gomez S, Villanueva Vazquez R, Jung KH, Babu KG, Wheatley-Price P, De Laurentiis M, Im YH, Kuemmel S, El-Saghir N, Liu MC, Carlson G, Hughes G, Diaz-Padilla I, Germa C, Hirawat S, Lu YS*. Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial. Lancet Oncol. 2018 Jul;19(7):904-915.
26
Lu YS, Chen TW, Lin CH, Yeh DC, Tseng LM, Wu PF, Rau KM, Chen BB, Chao TC, Huang SM, Huang CS, Shih TT, Cheng AL Taiwan Breast Cancer Consortium. Bevacizumab preconditioning followed by Etoposide and Cisplatin is highly effective in treating brain metastases of breast cancer progressing from whole-brain radiotherapy. Clin Cancer Res. 2015 Apr 15;21(8):1851-8.
